BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 102 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q2 2021. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $199,235 | +4.1% | 69,420 | +83.2% | 0.00% | – |
| Q2 2023 | $191,350 | +166.5% | 37,891 | -0.2% | 0.00% | – |
| Q1 2023 | $71,788 | +5.0% | 37,983 | 0.0% | 0.00% | – |
| Q4 2022 | $68,369 | +6.8% | 37,983 | 0.0% | 0.00% | – |
| Q3 2022 | $64,000 | -31.2% | 37,983 | +0.4% | 0.00% | – |
| Q2 2022 | $93,000 | -82.4% | 37,838 | -80.1% | 0.00% | – |
| Q1 2022 | $527,000 | -50.9% | 189,946 | -5.7% | 0.00% | – |
| Q4 2021 | $1,074,000 | -37.6% | 201,455 | -1.0% | 0.00% | – |
| Q3 2021 | $1,722,000 | -32.8% | 203,454 | -3.2% | 0.00% | – |
| Q2 2021 | $2,563,000 | -45.5% | 210,287 | +8.5% | 0.00% | -100.0% |
| Q1 2021 | $4,700,000 | -28.1% | 193,744 | -5.0% | 0.00% | 0.0% |
| Q4 2020 | $6,539,000 | +5.1% | 204,020 | -0.8% | 0.00% | 0.0% |
| Q3 2020 | $6,220,000 | +12.3% | 205,743 | +56.6% | 0.00% | 0.0% |
| Q2 2020 | $5,538,000 | +81.2% | 131,345 | +7.2% | 0.00% | 0.0% |
| Q1 2020 | $3,057,000 | – | 122,506 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 634,191 | $1,820,128 | 2.14% |
| NEA Management Company, LLC | 4,448,757 | $12,767,933 | 0.99% |
| CHI Advisors LLC | 720,000 | $2,066,400 | 0.82% |
| Bellevue Group AG | 8,135,839 | $23,349,858 | 0.38% |
| Parkman Healthcare Partners LLC | 520,587 | $1,494,085 | 0.27% |
| Artal Group S.A. | 2,046,517 | $5,874 | 0.25% |
| RA Capital Management | 3,525,754 | $10,118,914 | 0.20% |
| Ikarian Capital, LLC | 555,572 | $1,594,492 | 0.19% |
| TANG CAPITAL MANAGEMENT LLC | 400,000 | $1,148,000 | 0.16% |
| Newtyn Management, LLC | 205,000 | $588,350 | 0.14% |